Idebenone in Friedreich's ataxia

@article{Tonon2008IdebenoneIF,
  title={Idebenone in Friedreich's ataxia},
  author={Caterina Tonon and Raffaele Lodi},
  journal={Expert Opinion on Pharmacotherapy},
  year={2008},
  volume={9},
  pages={2327 - 2337}
}
Background: Friedreich's ataxia is an autosomal recessive neurodegenerative disease where impaired mitochondrial function and excessive production of free radicals play a central pathogenetic role. Idebenone, a synthetic analogue of coenzyme Q, is a powerful antioxidant that was first administrated to Friedreich's ataxia patients less than 10 years ago. Objective: The aim of this study was to evaluate the efficacy of idebenone administration and define the optimal dosage. Methods: A critical… Expand
New developments in pharmacotherapy for Friedreich ataxia
TLDR
In this review article, the authors discuss the current and prior in vivo and in vitro research studies related to the treatment of FRDA, with a particular interest in future implications of each therapy. Expand
Neuro-Ophthalmological Findings in Friedreich’s Ataxia
  • P. Rojas, R. de Hoz, +8 authors Ana I Ramírez
  • Medicine
  • Journal of personalized medicine
  • 2021
TLDR
This review provides a brief overview of the main aspects of FRDA and then focuses on the ocular involvement of this pathology and the possible use of retinal biomarkers. Expand
Intermediate-dose idebenone and quality of life in Friedreich ataxia.
TLDR
Functional ability, as measured by activities of daily living scores, appeared to have the most influence on the perception of physical quality of life, which may be important in planning future therapeutic trials. Expand
Antioxidant Defense Mechanisms and its Dysfunctional Regulation in the Mitochondrial Disease, Friedreich's Ataxia.
TLDR
Redox stress is associated with the pathogenesis of a wide variety of disease states, including Friedreich's ataxia (FA) and sideroblastic anemia, where iron metabolism is dysregulated and leads to mitochondrial iron accumulation. Expand
Iron–sulfur cluster synthesis, iron homeostasis and oxidative stress in Friedreich ataxia
TLDR
How defects in ISC synthesis could be a major contributor to the pathophysiology of FRDA via (i) loss of ISC-dependent enzymes, (ii) mitochondrial and cellular iron dysregulation, and (iii) enhanced iron-mediated oxidative stress is discussed. Expand
Emerging Mitochondrial Therapeutic Targets in Optic Neuropathies.
TLDR
The general principles of mitochondrial biology relevant to retinal ganglion cell function are reviewed and an overview of the major optic neuropathies with mitochondrial involvement, LHON and ADOA are provided, whilst highlighting the emerging link between mitochondrial dysfunction and glaucoma. Expand
Ocular Involvement in Friedreich Ataxia Patients and Its Relationship with Neurological Disability, a Follow-Up Study
TLDR
The VF and the OCT could be useful biomarkers in Friedreich ataxia, both for their correlation with neurological disease as well as for their ability to evaluate disease progression. Expand
A Strategy for Suppressing Redox Stress within Mitochondria.
TLDR
The aza analogue of the experimental neuroprotective drug idebenone quenches lipid peroxidation more effectively than α-tocopherol and potently suppresses reactive oxygen species in cells under oxidative stress via a catalytic cycle in which both forms of oxidative stress are suppressed simultaneously. Expand
Electron transfer mediators and other metabolites and cofactors in the treatment of mitochondrial dysfunction.
TLDR
The rationale for the use of ETC cofactors, other metabolites secondarily decreased in MDs, antioxidants, and agents acting on lactic acidosis are reviewed. Expand
Cellular stress responses, hormetic phytochemicals and vitagenes in aging and longevity.
TLDR
How hormetic dose responses are mediated for endogenous cellular defense pathways including sirtuin, Nrfs and related pathways that integrate adaptive stress responses in the prevention of neurodegenerative diseases is described in mechanistic detail. Expand
...
1
2
...

References

SHOWING 1-10 OF 113 REFERENCES
Idebenone and reduced cardiac hypertrophy in Friedreich's ataxia
TLDR
There is a good case for giving idebenone continuously in a dose of 5–10 mg/kg/day in patients with Friedreich's ataxia at the onset of hypertrophic cardiomyopathy, as the drug has no serious side effects. Expand
Heart Hypertrophy and Function Are Improved by Idebenone in Friedreich's Ataxia
TLDR
An open trial of idebenone (oral supplementation; 5 mg/kg/day) in a large series of FRDA patients and followed their left ventricular mass and function, demonstrating the efficiency of Idebenone in controlling heart hypertrophy in FRDA. Expand
Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial
TLDR
Treatment with higher doses of idebenone was generally well tolerated and associated with improvement in neurological function and ADL in patients with FA, suggesting that higher doses may be necessary to have a beneficial effect on neurological function. Expand
Friedreich's ataxia: idebenone treatment in early stage patients.
TLDR
Idebenone treatment at early stages of the disease seems to reduce the progression of cerebellar manifestations and further blind trials with a greater number of patients and higher doses are needed to fully assess the therapeutic potential of idebenone in Friedreich's ataxia. Expand
Idebenone in patients with Friedreich ataxia
TLDR
P magnetic resonance spectroscopy demonstrated mitochondrial impairment in vivo in skeletal muscle of all FA patients, but no recovery with idebenone, and Echocardiography did not confirm a preliminary study reporting improvement of FA-associated cardiomyopathy with Idebenone. Expand
Effect of idebenone on cardiomyopathy in Friedreich's ataxia: a preliminary study
TLDR
The in-vitro data suggest that both iron chelators and antioxidant drugs that may reduce iron are potentially harmful in patients with Friedreich's ataxia and that idebenone protects heart muscle from iron-induced injury. Expand
Idebenone treatment in paediatric and adult patients with Friedreich ataxia: long-term follow-up.
  • M. Pineda, J. Arpa, +12 authors R. Artuch
  • Medicine
  • European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society
  • 2008
TLDR
The results indicate that longer-term idebenone treatment prevented progression of cardiomyopathy in both paediatric and adult patients, whereas its stabilizing effect on neurological dysfunction was present only in the paediatric population, mainly before puberty. Expand
Friedreich's ataxia.
TLDR
This review discusses the major and rapid progress made in Friedreich's ataxia from gene mapping and identification of the gene to pathogenesis and encouraging therapeutic implications. Expand
Antioxidant enzymes in blood of patients with Friedreich's ataxia
TLDR
Data show an impairment in vivo of antioxidant enzymes in patients with Friedreich's ataxia and provide evidence of an increased sensitivity to oxidative stress, supporting a consistent role of free radical cytotoxicity in the pathophysiology of the disease. Expand
Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up.
TLDR
This therapy resulted in sustained improvement in mitochondrial energy synthesis that was associated with a slowing of the progression of certain clinical features and a significant improvement in cardiac function. Expand
...
1
2
3
4
5
...